FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Lowinger Timothy B						2. Issuer Name and Ticker or Trading Symbol  Mersana Therapeutics, Inc. [ MRSN ]								heck all app Direc	ationship of Reporting k all applicable) Director Officer (give title		son(s) to Is: 10% O Other (	wner	
	F RSANA TI MORIAL D		3. Date of Earliest Transaction (Month/Day/Year) 08/27/2018								^ belov	below) below)  Chief Scientific Officer							
(Street) CAMBRIDGE MA 02139 (City) (State) (Zip)							4. If Amendment, Date of Original Filed (Month/Day/Year)								dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day					ction	tion 2A. Deemed Execution Date,			3. Transaction Code (Instr.					5. Amo 5) Securi Benefi	ount of ties cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Transa	action(s) 3 and 4)			(Instr. 4)	
Common Stock 08/27/20					2018	)18		M		3,500	A	\$7.4	3 1	5,991		D			
Common Stock 08/27/20					2018	018		S <sup>(1)</sup>		3,500	D	\$13.1	5 <sup>(2)</sup> 1	2,491		D			
		7	able II								posed of converti	•		y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deer Execution if any (Month/I	on Date,		ransaction ode (Instr.		n of		Exerci on Da Day/Yo		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price o Derivative Security (Instr. 5)		i G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares						
Option to purchase	\$7.43	08/27/2018			M			3,500	(3)		05/11/2021	Common Stock	3,500	\$0	1,611		D		

## **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Lowinger's company approved trading plan under Rule 10b5-1.
- 2. This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$13.00 to \$13.50, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any other security holder of Mersana Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 3. The option vested 25% on May 12, 2012 and in equal quarterly installments thereafter.

/s/ Eva M. Jack , as Attorneyin-Fact

08/29/2018

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.